Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M, di Giandomenico S, D'Incalci M. Marchini S, et al. Among authors: zambelli a. Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13. Eur J Cancer. 2013. PMID: 22897840
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G. Mello-Grand M, et al. Among authors: zambelli a. Breast Cancer Res Treat. 2010 Jun;121(2):399-411. doi: 10.1007/s10549-010-0887-y. Epub 2010 Apr 29. Breast Cancer Res Treat. 2010. PMID: 20428938
Targeting triple negative breast cancer: is p53 the answer?
Turner N, Moretti E, Siclari O, Migliaccio I, Santarpia L, D'Incalci M, Piccolo S, Veronesi A, Zambelli A, Del Sal G, Di Leo A. Turner N, et al. Among authors: zambelli a. Cancer Treat Rev. 2013 Aug;39(5):541-50. doi: 10.1016/j.ctrv.2012.12.001. Epub 2013 Jan 12. Cancer Treat Rev. 2013. PMID: 23321033 Review.
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, Fotia V, Romualdi C, Martini P, Noris M, Paracchini L, Craparotta I, Petrillo M, Milani R, Perego P, Ravaggi A, Zambelli A, Ronchetti E, D'Incalci M, Marchini S. Beltrame L, et al. Among authors: zambelli a. Ann Oncol. 2015 Jul;26(7):1363-71. doi: 10.1093/annonc/mdv164. Epub 2015 Apr 6. Ann Oncol. 2015. PMID: 25846551 Free article.
Trabectedin for the treatment of breast cancer.
D'Incalci M, Zambelli A. D'Incalci M, et al. Among authors: zambelli a. Expert Opin Investig Drugs. 2016;25(1):105-15. doi: 10.1517/13543784.2016.1124086. Epub 2015 Dec 22. Expert Opin Investig Drugs. 2016. PMID: 26592307 Review.
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M. Romano M, et al. Among authors: zambelli a. Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10. Br J Cancer. 2017. PMID: 28072764 Free PMC article.
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.
Moccia F, Fotia V, Tancredi R, Della Porta MG, Rosti V, Bonetti E, Poletto V, Marchini S, Beltrame L, Gallizzi G, Da Prada GA, Pedrazzoli P, Riccardi A, Porta C, Zambelli A, D'Incalci M. Moccia F, et al. Among authors: zambelli a. Eur J Cancer. 2017 May;77:155-164. doi: 10.1016/j.ejca.2017.01.025. Epub 2017 Feb 28. Eur J Cancer. 2017. PMID: 28258798
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group. Cazzaniga ME, et al. Among authors: zambelli a. Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13. Breast. 2017. PMID: 28711793
299 results